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Objectives We investigated whether statin therapy could be beneficial in patients with acute myocardial infarction (AMI)
who have baseline low-density lipoprotein cholesterol (LDL-C) levels below 70 mg/dl.
Background Intensive lipid-lowering therapy with a target LDL-C value 70 mg/dl is recommended in patients with very
high cardiovascular risk. However, whether to use statin therapy in patients with baseline LDL-C levels below
70 mg/dl is controversial.
Methods We analyzed 1,054 patients with AMI who had baseline LDL-C levels below 70 mg/dl and survived at discharge
from the Korean Acute MI Registry between November 2005 and December 2007. They were divided into
2 groups according to the prescribing of statins at discharge (statin group n  607; nonstatin group n  447).
The primary endpoint was the composite of 1-year major adverse cardiac events, including death, recurrent MI,
target vessel revascularization, and coronary artery bypass grafting.
Results Statin therapy significantly reduced the risk of the composite primary endpoint (adjusted hazard ratio [HR]: 0.56;
95% confidence interval [CI]: 0.34 to 0.89; p  0.015). Statin therapy reduced the risk of cardiac death (HR:
0.47; 95% CI: 0.23 to 0.93; p  0.031) and coronary revascularization (HR: 0.45, 95% CI: 0.24 to 0.85; p 
0.013). However, there were no differences in the risk of the composite of all-cause death, recurrent MI, and
repeated percutaneous coronary intervention rate.
Conclusions Statin therapy in patients with AMI with LDL-C levels below 70 mg/dl was associated with improved clinical
outcome. (J Am Coll Cardiol 2011;58:1664–71) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.057Lowering of low-density lipoprotein cholesterol (LDL-C)
with a 3-hydroxy-3-methylglutaryl–coenzyme A reductase
inhibitor (statin) reduces the risk of death and cardiovascu-
lar events in both the primary setting and acute coronary
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October 11, 2011:1664–71 Statins in AMI Patients With Very Low LDL-Chigh-risk patients, such as those with ACS, the American
College of Cardiology/American Heart Association (ACC/
AHA) guidelines have set a value of 70 mg/dl as the
therapeutic goal for LDL-C (5,6).
See page 1672
In real clinical practice, physicians often encounter pa-
tients with ACS with LDL-C levels below 70 mg/dl. What
is the physicians’ optimal choice for these patients? A post
hoc multivariable analysis of the PROVE IT–TIMI 22
(Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy–Thrombolysis In Myocardial Infarction 22) trial re-
vealed no evidence of benefit in patients with baseline
LDL-C 66 mg/dl, indicating that further LDL-C reduc-
ion may not add any clinical benefit (7). Meanwhile, several
tudies reported that statin therapy resulted in favorable
outcomes regardless of baseline LDL-C levels (8–10).
Therefore, the influence of baseline LDL-C on the clinical
benefit of lipid-lowering therapy remains controversial.
Under these circumstances, we investigated whether statin
therapy could be beneficial in patients with acute myocardial
infarction (AMI) who have baseline LDL-C levels below 70
mg/dl.
Methods
Study population. A total of 14,885 patients enrolled in
he KAMIR (Korea Acute Myocardial Infarction Registry)
rom November 2005 to December 2007. A total of 1,054
atients with AMI who had serum LDL-C levels below 70
g/dl comprised the study population. They were divided
nto 2 groups according to the prescribing of a statin at
ischarge (statin group n  607; nonstatin group n  447).
he eligible patients were 18 years of age at admission
nd had suggestive symptoms with or without ST-segment
levation 2 mm in 2 precordial leads, ST-segment
levation 1 mm in 2 limb leads, or new left bundle
ranch block on the 12-lead electrocardiogram with con-
omitant increases in the level of at least one cardiac
nzyme. Fasting lipid profiles were obtained within 24 h of
dmission. Patients who already had a diagnosis of dyslip-
demia or had received statin therapy before hospital admis-
ion were included in the present study. The criteria for
xclusion included concomitant use of fibric acid derivatives,
ipid profiles obtained more than 24 h after admission or in
nonfasting state, and estimated life expectancy 12
onths.
The KAMIR, launched in November 2005, was a Korean
rospective, multicenter data collection registry reflecting
eal world treatment practices and outcomes in Asian
atients diagnosed with AMI. The registry included 50
ommunity and teaching hospitals with facilities for primary
ercutaneous coronary intervention (PCI) and on-site car-
iac surgery. The KAMIR was supported by a research
rant from the Korean Circulation Society in commemora- dion of its 50th anniversary. Data
ere collected by a trained study
oordinator using a standardized
ase report form and protocol.
he study protocol was approved
y the ethics committee at each
articipating institution.
edical treatment and PCI
rocedure. All patients received
300-mg loading dose of aspirin,
00- to 600-mg loading dose of
lopidogrel, and heparin. The
aintenance dose was 100 mg/
ay for aspirin and 75 mg/day for
lopidogrel. Aspirin and clopi-
ogrel were administered to all
atients for 6 months as per
xisting guidelines. Statins were
dministered for at least 1 month
fter discharge to the statin group. After 1 month, the use of
tatins was left to the discretion of physicians. The post-
ntervention medication included aspirin, clopidogrel, beta-
lockers, angiotensin-converting enzyme inhibitors, and
ngiotensin II receptor blockers. After discharge, the pa-
ients continued receiving the same medications that they
eceived during hospitalization, except for some intravenous
r temporary medications. Coronary artery stenting was
erformed using standard techniques. The decisions for
re-dilation, direct stenting, post-adjunctive balloon infla-
ion, and administration of glycoprotein IIb/IIIa receptor
lockers were left to the discretion of individual physicians.
linical follow-up was performed at 1, 6, and 12 months
nd when angina-like symptoms occurred.
tudy definition and endpoints. AMI was diagnosed by
he presence of characteristic clinical presentation, serial
hanges on electrocardiogram suggesting infarction, and
ncreases in cardiac enzyme levels. Dyslipidemia was defined
s a diagnosis previously made by a physician or treatment
ith lipid-lowering medications. The primary endpoint was
he composite of major adverse cardiac events (MACE)
uring the 12 months of clinical follow-up. MACE was
efined as the composite of all-cause death, MI, and
epeated PCI or coronary artery bypass grafting (CABG).
ll-cause deaths were considered cardiac deaths unless a
oncardiac death could be defined clearly. Recurrent MI
as defined as recurrent symptoms with new electrocardio-
raphic changes compatible with MI or cardiac markers at
east twice the upper limit of normal. Target vessel revas-
ularization (TVR) was defined as any repeated intervention
riven by the lesions located in the treated vessel within and
eyond the target limits. The secondary endpoints were
ndividual components of the primary endpoint, including
ardiac death, all-cause death, recurrent MI, and coronary
evascularization procedures.
tatistical analysis. All statistical analyses were con-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
CABG  coronary artery
bypass grafting
hs-CRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
TVR  target vessel
revascularizationucted with SPSS version 16.0 (SPSS Inc., Chicago,
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Statins in AMI Patients With Very Low LDL-C October 11, 2011:1664–71Illinois). For continuous variables, differences between
groups were evaluated by an unpaired t test or Mann-
Whitney rank-sum test. For discrete variables, differences
were expressed as counts and percentages and were
analyzed with a chi-square or Fisher exact test between
groups as appropriate. We constructed Kaplan-Meier
curves for patients in the statin or nonstatin therapy
group to the composite of the primary endpoint, and
difference between the groups was assessed by log-rank
test. A propensity score analysis was performed to adjust
potential confounders using a logistic regression model.
All available variables considered potentially relevant
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
St
(n
Male* 437 (7
Age, yrs† 71.0 (6
Medical history*
Hypertension 330 (5
Diabetes mellitus 209 (3
Dyslipidemia 81 (1
Smoking 331 (5
Previous history of MI 51 (8
Previous history of PCI 78 (1
Previous CABG 7 (1
Previous history of CVA 51 (
Previous history of PVD 11 (
Previous history of HF 19 (
Killip class III on presentation* 128 (
LVEF, %‡ 50
Laboratory findings†
Total cholesterol, mg/dl 123.0 (
HDL-C, mg/dl 40.0 (
LDL-C, mg/dl 58.0 (
Triglycerides, mg/dl 84.0 (
Peak creatine kinase-MB, ng/ml 46.3 (
Peak troponin I, ng/ml 13.0 (
Serum creatinine, mg/dl 1.0 (
hs-CRP, mg/dl 1.4 (
NT-proBNP, pg/ml 568.5 (
Indication for PCI*
ST-segment elevation MI 329 (
Non–ST-segment elevation MI 277 (
Medications*
Aspirin 595 (
Clopidogrel 581 (
Beta-blocker 480 (
Angiotensin-converting enzyme inhibitor 453 (
Angiotensin receptor blocker 146 (
Glycoprotein IIb/IIIa inhibitors 58 (
Unfractionated heparin 364 (
Low-molecular-weight heparin 188 (
Heparin§ 459 (
Values are n (%), median (25 to 75 percentile), or mean  SD. *C
Mann-Whitney test. ‡Comparison made using the t test. §Sum of low
CABG  coronary artery bypass grafting; CVA  cerebrovascular a
hs-CRP  high-sensitivity C-reactive protein; LDL-C  low-density lipoprotein c
infarction; NT-proBNP  N-terminal pro–B-type natriuretic peptide; PCI  perwere included: age, sex, hypertension, diabetes mellitus,
dyslipidemia, smoking, previous history of MI, Killip
class on presentation, left ventricular ejection fraction,
lipid profiles, use of glycoprotein IIb/IIIa inhibitors,
medications, success rate of PCI, involvement of left
main coronary artery, multivessel disease, lesion complex-
ity, and pre- and post-procedural Thrombolysis In Myo-
cardial Infarction (TIMI) flow grade. The predicted
accuracy of the logistic model was assessed using the area
under the receiver-operating characteristic curve (C sta-
tistic), which was 0.760. Cox proportional hazards re-
gression was used to compute hazard ratios (HRs) as
oup
7)
Nonstatin Group
(n  447) p Value
314 (70.4) 0.573
8.0) 71.0 (62.0–80.0) 0.809
225 (50.3) 0.195
154 (34.5) 0.995
42 (9.4) 0.048
243 (54.4) 0.957
16 (3.6) 0.002
37 (8.3) 0.019
3 (0.7) 0.531
91 (9.2) 0.661
6 (1.3) 0.550
18 (4.0) 0.434
103 (23.0) 0.448
2.2 50.6 12.9 0.980
123.0) 122.0 (108.0–136.0) 0.453
8.0) 41.0 (32.0–50.0) 0.929
5.0) 59.0 (48.0–65.0) 0.709
26.5) 77.0 (54.0–115.0) 0.083
49.1) 36.5 (11.0–148.4) 0.331
.7) 12.5 (2.5–49.5) 0.834
) 1.1 (0.9–1.3) 0.852
) 1.3 (0.2–7.0) 0.525
2,600.0) 659.5 (169.8–2,688.0) 0.386
0.205
224 (50.3)
221 (49.7)
430 (96.2) 0.073
418 (93.5) 0.112
311 (69.6) 0.001
312 (69.8) 0.082
100 (22.4) 0.524
40 (8.9) 0.737
240 (53.7) 0.042
159 (35.6) 0.116
330 (73.8) 0.507
son made using the chi-square test. †Comparison made using the
lar-weight heparin and unfractionated heparin.
ts; HDL-C  high-density lipoprotein cholesterol; HF  heart failure;atin Gr
 60
2.0)
0.0–7
4.4)
4.4)
3.3)
4.5)
.4)
2.9)
.2)
8.4)
1.8)
3.1)
21.1)
.6 1
108.0–
33.0–4
48.0–6
56.0–1
13.2–1
2.1–42
0.9–1.3
0.2–8.5
144.0–
54.3)
45.7)
98.0)
95.7)
79.1)
74.6)
24.1)
9.6)
60.0)
31.0)
75.6)
ompari
-molecu
ccidenholesterol; LVEF  left ventricular ejection fraction; MI  myocardial
cutaneous coronary intervention; PVD  peripheral vascular disease.
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October 11, 2011:1664–71 Statins in AMI Patients With Very Low LDL-Cestimates for each endpoint. The HRs were adjusted for
propensity score and important risk covariables that had
significant effects (p  0.1) in the univariate analysis for
clinical outcomes. All analyses were 2-tailed, with clinical
significance defined as p  0.05.
esults
aseline clinical characteristics. A total of 1,054 patients
ith AMI were included in the present study. They were
ivided into 2 groups according to the prescribing of statins
t discharge (statin group n  607; nonstatin group n 
47). In the statin group, 541 patients (89.1%) received
tatins during hospital admission, whereas 66 patients
10.9%) did not. None of the nonstatin group received
tatins during hospital admission. No significant differences
n the baseline characteristics were found between the
roups, except that the statin group had a higher incidence
f prior dyslipidemia and MI. Laboratory findings were also
omparable between the groups. No significant differences
n the in-hospital and discharge medical treatment were
ound between the groups, except that the statin group more
ommonly received beta-blockers (Table 1).
rocedural characteristics. A total of 809 patients (76.8%)
nderwent PCI, with 83.6% undergoing stent implantation.
he success rate of PCI was comparable in both groups
96.2% in the statin group vs. 95.4% in the nonstatin group;
 0.583). Analysis of angiographic findings showed no
ifferences in location of culprit lesions, prevalence of
ultivessel disease, ACC/AHA lesion type, distribution of
re- and post-procedural TIMI flow grade, stent type and
ength, and stent diameter (Table 2).
linical outcomes. During the 12-month follow-up pe-
iod, a primary endpoint event occurred in 58 patients
Figure 1 Estimates of the Rate of the Primary Endpoint Events
The primary endpoint was the composite of death, recurrent myocardial infarction,
PCI  percutaneous coronary intervention.14.5%) in the statin group and 57 patients (20.4%) in theonstatin group (log-rank p  0.024) (Fig. 1). Statin
herapy significantly reduced the risk of the composite
rimary endpoint (adjusted HR: 0.56; 95% confidence
nterval [CI]: 0.34 to 0.89; p  0.015) (Table 4). Outcomes
or the selected secondary endpoints are shown in Table 4.
ardiac death occurred in 16 patients (4.0%) in the statin
roup and 21 patients (7.5%) in the nonstatin group. Statin
herapy reduced the risk of cardiac death (HR: 0.47; 95%
I: 0.23 to 0.93; p  0.031). Coronary revascularization
ccurred in 27 patients (6.8%) in the statin group and 28
atients (10.0%) in the nonstatin group. Statin therapy
educed the risk of coronary revascularization (HR: 0.45;
5% CI: 0.24 to 0.85; p  0.013). Although statin therapy
educed the risk of cardiac death and coronary revascular-
zation, there were no differences in the risk of the compos-
te of all-cause death, recurrent MI, and repeated PCI rate.
Outcomes for each component of the secondary end-
oints at the follow-up of 6 months and 12 months are
ummarized in Table 3. At 6 months, statin therapy
ignificantly decreased cardiac death (3.1% vs. 5.9%; p 
.031), CABG (1.8% vs. 2.8%; p  0.012), and the
composite of MACE (10.9% vs. 13.9%; p 0.048), with no
ifferences in all-cause death, MI, re-PCI, and TVR.
ikewise, at 12 months, statin therapy significantly de-
reased cardiac death (4.0% vs. 7.5%; p  0.048), CABG
(2.0% vs. 3.9%; p  0.003), and the composite of MACE
(14.5% vs. 20.4%; p  0.014), with no differences in
all-cause death, MI, re-PCI, and TVR.
Subgroup analysis showed that the beneficial effects of
statin therapy appeared to be prominent in men, the elderly,
those without diabetes mellitus, those without hypertension,
those without prior dyslipidemia, smokers or ex-smokers,
those with an initial diagnosis of ST-segment elevation
oronary revascularization. MACE  major adverse cardiac event(s);and cmyocardial infarction (STEMI), and those with higher
1668 Lee et al. JACC Vol. 58, No. 16, 2011
Statins in AMI Patients With Very Low LDL-C October 11, 2011:1664–71serum levels of high-sensitivity C-reactive protein (hs-
CRP). However, the p value for homogeneity was not
significant in all subgroup analyses. Stratified Cox analyses
for the primary endpoint favored statin therapy in all
subgroup analyses (Fig. 2).
Discussion
Current guidelines provide recommendations for initiat-
ing statin therapy for targeting the optional therapeutic
Procedural CharacteristicsTable 2 Procedural Characteristics
Statin Group
(n  607)
Nonstatin Group
(n  447) p Value
Location of culprit lesion
Left anterior descending artery 229 (44.0) 157 (47.6) 0.301
Left circumflex artery 64 (12.3) 50 (15.2) 0.231
Right coronary artery 216 (41.5) 116 (35.2) 0.066
Left main coronary artery 12 (2.3) 7 (2.1) 0.861
Multivessel disease 277 (53.1) 187 (56.2) 0.376
ACC/AHA lesion types
A 28 (5.7) 14 (4.8) 0.584
B1 89 (18.2) 48 (16.5) 0.545
B2 147 (30.1) 84 (28.9) 0.724
C 225 (46.0) 145 (49.8) 0.302
B2/C 372 (76.1) 229 (78.7) 0.400
Pre-procedural TIMI flow grade
0 217 (43.9) 117 (38.0) 0.097
1 55 (11.1) 39 (12.7) 0.513
2 70 (14.2) 52 (16.9) 0.298
3 152 (30.8) 100 (32.5) 0.614
Stent type 0.182
Bare-metal stent 35 (8.5) 31 (11.7)
Drug-eluting stent 375 (91.5) 235 (88.3)
Stent length, mm* 25.4 7.2 24.9 5.9 0.296
Stent diameter, mm* 3.2 0.4 3.1 0.4 0.188
No. of stents* 1.5 0.8 1.5 0.8 0.358
Post-procedural TIMI flow grade
0 16 (3.5) 7 (2.4) 0.389
1 7 (1.5) 1 (0.3) 0.159
2 18 (3.9) 17 (5.8) 0.238
3 419 (91.1) 270 (91.5) 0.835
Values are n (%) or mean  SD.
ACC/AHA  American College of Cardiology/American Heart Association; TIMI  Thrombolysis
In Myocardial Infarction.
Cumulative Secondary Endpoints at 12 MonthsTable 4 Cumulative Secondary Endpoints at
Unadjusted HR (95% CI
Death 0.62 (0.35–1.09)
Cardiac death 0.54 (0.28–0.90)
Noncardiac death 0.98 (0.31–3.07)
MI 1.27 (0.43–3.78)
Coronary revascularization 0.57 (0.33–0.98)
Repeated PCI 0.77 (0.40–1.48)
TVR 0.55 (0.22–1.40)
CABG 0.25 (0.08–0.79)
MACE 0.66 (0.45–0.95)CI  confidence interval; HR  hazard ratio; other abbreviations as in Tablesgoal of LDL-C 70 mg/dl in patients at high risk of
cardiovascular events (5,6). Although physicians follow
the guidelines, the decision to treat very high-risk pa-
tients with statins who already have baseline LDL-C
levels below 70 mg/dl remains controversial in regard to
benefit, risk, and cost. In patients with ACS with
LDL-C levels below 70 mg/dl, the present study showed
that statin therapy significantly reduced the risk of the
endpoints defined as the composite of all-cause death,
MI, and coronary revascularization.
Until now, no trials have been randomized with regard
to the degree of baseline LDL-C levels. Some observa-
tional studies and post-hoc analyses of randomized clin-
ical trials (RCTs) have reported the influence of baseline
LDL-C levels on the clinical benefit of lipid-lowering
therapy (7–12). Tsai et al. (12) examined the relationship
between statin therapy at discharge and clinical outcomes
in 155 patients with ACS with baseline LDL-C levels
80 mg/dl. Statin-treated patients had a lower incidence
of death, re-infarction, or stroke at 6 months compared
Clinical Outcomes at 6 and 12 MonthsAccording o Statin MedicationTable 3 Clinical Outcomes at 6 and 12 MonthsAccording to Statin Medication
Statin Group
(n  607)
Nonstatin Group
(n  447) p Value
6-month outcomes
Cardiac death 14 (3.1) 19 (5.9) 0.031
Total death 19 (4.2) 22 (6.8) 0.071
MI 9 (2.0) 2 (0.6) 0.386
Repeated PCI 14 (3.1) 13 (4.0) 0.336
TVR 5 (1.1) 8 (2.5) 0.081
CABG 8 (1.8) 9 (2.8) 0.012
MACE 50 (10.9) 45 (13.9) 0.048
12-month outcomes
Cardiac death 16 (4.0) 21 (7.5) 0.048
Total death 23 (5.8) 26 (9.3) 0.101
MI 9 (2.3) 5 (1.8) 0.644
Repeated PCI 19 (4.8) 17 (6.1) 0.232
TVR 8 (2.0) 10 (3.6) 0.209
CABG 8 (2.0) 11 (3.9) 0.003
MACE 58 (14.5) 57 (20.4) 0.014
Values are n (%). All comparisons were made using the chi-square test.
MACE  major adverse cardiac event(s); TVR  target vessel revascularization; other abbrevia-
tions as in Table 1.
rding to Statin Medicationonths According to Statin Medication
p Value Adjusted HR (95% CI) p Value
0.092 0.56 (0.26–1.20) 0.133
0.036 0.47 (0.23–0.93) 0.031
0.966 0.89 (0.20–4.09) 0.885
0.671 1.38 (0.45–4.19) 0.570
0.044 0.45 (0.24–0.85) 0.013
0.435 0.63 (0.29–1.35) 0.232
0.202 0.51 (0.19–1.40) 0.191
0.018 0.15 (0.04–0.55) 0.004
0.026 0.56 (0.34–0.89) 0.015Acco12 M
)1 and 3.
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October 11, 2011:1664–71 Statins in AMI Patients With Very Low LDL-Cwith non–statin-treated patients (29.0% vs. 9.5%; p 
0.005). Leeper et al. (10) also reported improved survival
(HR: 0.65; 95% CI: 0.53 to 0.80) with statin therapy in
patients with LDL-C levels below 60 mg/dl. Meanwhile,
a post hoc multivariable analysis of the PROVE IT–
TIMI 22 trial revealed no evidence of benefit in patients
with baseline LDL-C 66 mg/dl (7). Considering these
Figure 2 Estimates of Hazard Ratios for the Primary Endpoint i
Hazard ratios are shown on a logarithmic scale. CI  confidence interval; hs-CRP
NSTEMI  non–ST-segment elevation myocardial infarction; STEMI  ST-segmentnconsistent results, the present study added evidence tothe effect of statin therapy for patients with ACS who
have baseline LDL-C levels below 70 mg/dl.
In the present study, statin therapy significantly reduced
the risk of the composite primary endpoint, mainly driven
by the risk reduction of cardiac death and coronary revas-
cularization. These results are consistent with many RCTs,
such as the MIRACL (Myocardial Ischemia Reduction
ected Subgroups
-sensitivity C-reactive protein;
ion myocardial infarction.n Sel
 high
elevatwith Aggressive Cholesterol Lowering) trial (13), A to Z
1670 Lee et al. JACC Vol. 58, No. 16, 2011
Statins in AMI Patients With Very Low LDL-C October 11, 2011:1664–71(Aggrastat to Zocor) trial (14), and PROVE IT-TIMI trial
(4). However, differences are found between the present
study and these RCTs in which component of the primary
endpoint led the composite risk reduction. The component
was cardiovascular death in the A to Z trial and coronary
revascularization in the PROVE IT-TIMI trial. None of
these trials showed a risk reduction in all-cause death and
recurrent MI. In a pooled analysis of 7 RCTs of statin
therapy in patients with ACS, statin therapy reduced the
risk of death (HR: 0.75; 95% CI: 0.61 to 0.93) and
revascularization (HR: 0.86; 95% CI: 0.78 to 0.96), with no
differences in recurrent MI and stroke (15). Compared with
these RCTs and meta-analyses, the present study showed a
similar trend of risk reduction related to each component of
the primary endpoint and potentially extended the results of
these trials to patients with ACS with very low LDL-C
levels.
However, the mechanism by which the risk of cardiovas-
cular death and coronary revascularization is reduced is not
fully understood. It can be partly explained by the fact that
statins exhibit a number of biological effects, besides low-
ering serum levels of LDL-C, that may be relevant in the
setting of acute ischemic events. Statins improve vascular
endothelial function, attenuate vascular inflammation, sta-
bilize plaques, correct prothrombotic tendencies, and influ-
ence myocardial protection and remodeling (16–19). Usu-
ally patients with very low LDL-C levels are older and more
likely to have histories of other important comorbidities,
such as diabetes mellitus and hypertension, than patients
with higher LDL-C levels. Considering this, patients with
very low LDL-C levels might benefit as much or more from
statin therapy as patients with higher LDL-C levels. Thus,
it is not necessarily surprising that the beneficial effects of
statins in these high-risk patients became more potent after
controlling for the propensity score and covariates. How-
ever, we should be cautious about interpreting the men-
tioned pleiotropic effects of statins because those effects take
several months to occur. The present study showed that the
beneficial effect of statins was also apparent after 6 months.
We also analyzed the clinical outcome at 1 month, and there
were no significant differences in the primary endpoint
between the groups. This is consistent with and expands on
2 meta-analyses (20,21), both of which also showed that
beneficial effects of statins were apparent only after more
than 4 months.
In subgroup analyses, although differences were statisti-
cally significant in some groups and not in others, mainly
because of sample size, the beneficial effects of statin therapy
appeared to be prominent in men, the elderly, those without
diabetes mellitus, those without hypertension, those without
prior dyslipidemia, smokers or ex-smokers, those with
initial diagnoses of STEMI, and those with higher serum
levels of hs-CRP. This finding indicates that statin therapy
might be considered in patients with ACS who do not have
a history of diabetes mellitus, hypertension, or dyslipidemia.
They are often regarded as low-risk patients and are lesslikely to be prescribed statins. Statin therapy was also
favored in patients with higher serum levels of hs-CRP. The
JUPITER (Justification for the Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin) trial dem-
onstrated that statin therapy reduces vascular events in
apparently healthy men and women with low levels of
LDL-C who are at higher risk because of elevated hs-CRP
levels (22). Likewise, our study showed more prominent
beneficial effects in patients with ACS with very low
LDL-C levels and elevated hs-CRP levels.
The results of the present study cannot be extrapolated to
a clinical population presenting under more routine circum-
stances. The present study only included acute events of
AMI. Early studies have indicated that cholesterol levels
decrease significantly after ACS (23). Therefore, further
study is needed to evaluate the effect of statins in patients
with stable coronary artery disease and LDL-C 70 mg/dl.
Study limitations. First, the study lacked data on specific
statins and doses. Therefore, we could not evaluate
differences between intensive versus moderate statin ther-
apy. Second, we could only exclude the use of fibric acid
derivatives, leaving the use of bile acid sequestration
agents unknown. Fortunately, bile acid sequestration
agents are not commonly prescribed in Korea compared
with statins or fibric acid derivatives. Third, the present
study was designed to administer statins for at least 1
month after discharge for the statin group. After 1
month, the use of statins was left at the discretion of
physicians. Therefore, the beneficial effects of statins in
the present study are only attributable to the time period
of 1 month after discharge. Fourth, the present study was
analyzed retrospectively. The nonrandomized nature of
the registry data could have resulted in selection bias.
Although most confounders were included in the multi-
variate regression analysis, it is possible that some poten-
tial bias were included. Large-scale, prospective RCTs
are needed to clarify the effects of statins in patients with
ACS with varying degrees of baseline LDL-C levels.
Nonetheless, the present study has strengths in that the
nonrandomized design of the study included many pa-
tients who would not have been enrolled in randomized
trials, including the elderly and those with severe comor-
bidities. Also, the present study only included patients
with ACS, especially AMI; had a relatively large sample
size compared with other observational studies and the
PROVE IT–TIMI 22 trial (all enrolled patients, n 
2,986; patients with LDL-C 92 mg/dl, n  749); and
had relative homogeneity of the study population be-
tween the groups, despite the nonrandomized design.
Conclusions
The present study showed that statin therapy in patients
with AMI with LDL-C levels below 70 mg/dl was associ-
ated with improved clinical outcome. Statin therapy signif-
icantly reduced the risk of the composite of the MACE,
1671JACC Vol. 58, No. 16, 2011 Lee et al.
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coronary revascularization. However, further randomized
trials are needed based on the pre-treatment LDL-C levels
in patients with ACS, as well as in stable coronary artery
disease.
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APPENDIX
For a complete list of KAMIR investigators,
please see the online version of this article.
